Nomination Summary for Testosterone (N20401)

Nominated Substances: Testosterone, Testosterone propionate, Testosterone oenanthate

Nomination Date: 11/13/2003

Nominator: Private Individual

Rationale: The rapidly growing use of testosterone therapy has outpaced the meager scientific evidence about its benefits and risks. Testosterone therapy has been approved by the FDA only for treating a narrow group of clinical conditions marked by very low testosterone levels, yet doctors have been prescribing it much more widely. Last year more than 800,000 patients, mostly middle-aged men, were treated with testosterone. More studies are needed to determine the risks, such as prostate cancer and cardiovascular disease, associated with its use.

NTP Principles: not specified

Status: Received

Agents and Status

The following information relates to the specific agent and may include history from earlier or later nominations for this same agent.

CASRN: 58-22-0

Agent Name: Testosterone

  • No studies are available.

CASRN: 57-85-2

Agent Name: Testosterone propionate

  • No studies are available.

CASRN: 315-37-7

Agent Name: Testosterone oenanthate

  • No studies are available.